Topical nasal pharmaceutical composition for the treatment and prophylaxis of chronic rhinosinusitis (crs)

A pharmaceutical composition in topical nasal solution for adults, comprising:

• 180 mg Rifamycin per 100 mL of the composition;
• 27 mg Fluticasone Propionate per 100 mL of the composition;
• 4.5 mg Oxymetazoline Hydrochloride in per 100 mL of the composition;
• 0.30 mL bacterial antigen suspension per 100 mL of the composition;
• 18.70 mL 0.9% saline solution per 100 mL of the composition, and
• pharmaceutically acceptable excipients q.s.;
• wherein 0.30 mL bacterial antigen suspension per 100 ml of the composition provides antigens from respiratory germs selected from:
• Streptococcus pneumoniae 60 million per 100 mL of the composition;
• Branhamella catarrahalis 30 million per 100 mL of the composition;
• Haemophilus influenzae 60 million per 100 mL of the composition;
• Streptococcus (respiratory) 30 million per 100 mL of the composition;
• Klebsiella pneumoniae 60 million per 100 mL of the composition;
• and Micrococcus (respiratory) 60 million per 100 mL of the composition.

A pharmaceutical composition in topical nasal solution for children weighing between 15 kg and 30 kg, comprising:

• 180 mg Rifamycin per 100 mL of the composition;
• 27 mg Fluticasone Propionate per 100 mL of the composition;
• 2.25 mg Oxymetazoline Hydrochloride in per 100 mL of the composition;
• 0.30 mL bacterial antigen suspension per 100 mL of the composition;
• 23.20 mL 0.9% saline solution per 100 mL of the composition, and
• pharmaceutically acceptable excipients q.s.;
• wherein 0.30 mL bacterial antigen suspension per 100 mL of the composition provides antigens from respiratory germs selected from:
• Streptococcus pneumoniae 60 million per 100 mL of the composition;
• Branhamella catarrahalis 30 million per 100 mL of the composition;
• Haemophilus influenzae 60 million per 100 mL of the composition;
• Streptococcus (respiratory) 30 million per 100 mL of the composition;
• Klebsiella pneumoniae 60 million per 100 mL of the composition;
• and Micrococcus (respiratory) 60 million per 100 mL of the composition.

A pharmaceutical composition in nasal spray for children weighing less than 15 kg and adults with pre-existing conditions, comprising:

• 180 mg Rifamycin per 100 mL of the composition;
• 27 mg Fluticasone Propionate per 100 mL of the composition;
• 0.30 mL bacterial antigen suspension per 100 mL of the composition;
• 27.70 mL 0.9% saline solution per 100 mL of the composition, and
• pharmaceutically acceptable excipients q.s.;
• wherein 0.30 mL bacterial antigen suspension per 100 mL of the composition provides antigens from respiratory germs selected from:
• Streptococcus pneumoniae 60 million per 100 mL of the composition;
• Branhamella catarrahalis 30 million per 100 mL of the composition;
• Haemophilus influenzae 60 million per 100 mL of the composition;
• Streptococcus (respiratory) 30 million per 100 mL of the composition;
• Klebsiella pneumoniae 60 million per 100 mL of the composition;
• and Micrococcus (respiratory) 60 million per 100 mL of the composition.